Ren-Yi Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ren-Yi Su has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Jiayin Yang
Liver Transplant Center, Organ Transplant Center, West China Hospital of Sichuan University, Chengdu, China
2 shared publications - Xiao Xu
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 shared publications - Xuyong Wei
Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, China
2 shared publications Beng Yang
Department of Hepatobiliary and Pancreatic Surgery the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310006 China
1 shared publication- Bin Xie
School of Materials Science and Engineering Sichuan University of Science and Engineering Zigong China
1 shared publication - Bo Wang
Sarah Cannon Research Institute at Willamette Valley Cancer Institute and Research Center, Eugene, OR
1 shared publication
Latest Publications
- 30 July 2026
- Published by Wiley in Liver International
- Vol. 46 (9)
Steatosis in Cirrhosis: A Prognostic Marker for Liver‐Related Outcomes in Metabolic‐Dysfunction Associated Steatotic Liver Disease
Background and Aims: The predictive ability of histological components in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) has not been well studied. Here, we look at the ability of digital pathology through the components of qFIBs (qfibrosis, qInflammation, qBallooning, qSteatosis) in predicting the risk of Major Adverse Liver Outcomes (MALO). Method: 235 liver biopsy images were retrieved, and the composite end point of MALO, including overall death, hepatic encephalopathy (HE), ascites, variceal haemorrhage and hepatocellular carcinoma (HCC), was studied in parallel with the Non‐alcoholic Steatohepatitis Clinical Research Network (NASH‐CRN) score and qFIBs. Results: The predictive power of qFibrosis for MALOs (qF3/4 vs. qF0/1/2, HR 6.64, 95% CI 1.69–26.06, log rank p ‐value 0.001) was comparable to NASH‐CRN (F3/4 vs. F0/1/2, HR 7.02, 95% CI 2.37–20.84, log rank p ‐value < 0.001). Interestingly, a lower steatosis grade, rather than being a protective factor, correlated with poorer outcomes for both the qFIBs (qS0/1 vs. qS2/3 HR 17.24, 95% CI 3.12–95.32, log rank p value < 0.001) and NASH‐CRN (S0/1 vs. S2/3 HR 6.30, 95% CI 2.14–18.61, log rank p value < 0.001). Lower qSteatosis scores of qS1 and below among the cirrhotic group ( n = 35) also showed a six‐fold higher risk of MALOs (< 1.50 vs. ≥ 1.50, HR 6.40, 95% CI 1.08–37.92, log rank p value < 0.011), likely due to the reduction of steatosis in the cachectic state of a patient with end stage liver disease. Samples with lower percentages of macro‐vesicular vacuoles had a fourfold increased risk of MALOs (HR 4.41, 95% CI 1.06–18.43, log rank p value 0.017). Conclusion: Lower steatosis grades in higher fibrosis stages correlate significantly with the occurrence of MALO. Our findings instigate exploration of the process of fat resorption in MASLD and its relation to outcomes.
- 30 July 2026
- Published by Wiley in Liver International
- Vol. 46 (9)
Steatosis in Cirrhosis: A Prognostic Marker for Liver‐Related Outcomes in Metabolic‐Dysfunction Associated Steatotic Liver Disease
Background and Aims: The predictive ability of histological components in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) has not been well studied. Here, we look at the ability of digital pathology through the components of qFIBs (qfibrosis, qInflammation, qBallooning, qSteatosis) in predicting the risk of Major Adverse Liver Outcomes (MALO). Method: 235 liver biopsy images were retrieved, and the composite end point of MALO, including overall death, hepatic encephalopathy (HE), ascites, variceal haemorrhage and hepatocellular carcinoma (HCC), was studied in parallel with the Non‐alcoholic Steatohepatitis Clinical Research Network (NASH‐CRN) score and qFIBs. Results: The predictive power of qFibrosis for MALOs (qF3/4 vs. qF0/1/2, HR 6.64, 95% CI 1.69–26.06, log rank p ‐value 0.001) was comparable to NASH‐CRN (F3/4 vs. F0/1/2, HR 7.02, 95% CI 2.37–20.84, log rank p ‐value < 0.001). Interestingly, a lower steatosis grade, rather than being a protective factor, correlated with poorer outcomes for both the qFIBs (qS0/1 vs. qS2/3 HR 17.24, 95% CI 3.12–95.32, log rank p value < 0.001) and NASH‐CRN (S0/1 vs. S2/3 HR 6.30, 95% CI 2.14–18.61, log rank p value < 0.001). Lower qSteatosis scores of qS1 and below among the cirrhotic group ( n = 35) also showed a six‐fold higher risk of MALOs (< 1.50 vs. ≥ 1.50, HR 6.40, 95% CI 1.08–37.92, log rank p value < 0.011), likely due to the reduction of steatosis in the cachectic state of a patient with end stage liver disease. Samples with lower percentages of macro‐vesicular vacuoles had a fourfold increased risk of MALOs (HR 4.41, 95% CI 1.06–18.43, log rank p value 0.017). Conclusion: Lower steatosis grades in higher fibrosis stages correlate significantly with the occurrence of MALO. Our findings instigate exploration of the process of fat resorption in MASLD and its relation to outcomes.
- Open Access
- 15 February 2024
- Published by Wiley in Advanced Science
- Vol. 11 (16) , e2306915
Integrated Multiomics Reveals Silencing of has_circ_0006646 Promotes TRIM21‐Mediated NCL Ubiquitination to Inhibit Hepatocellular Carcinoma Metastasis
Recent studies suggest that circular RNA (circRNA)‐mediated post‐translational modification of RNA‐binding proteins (RBP) plays a pivotal role in metastasis of hepatocellular carcinoma (HCC). However, the specific mechanism and potential clinical therapeutic significance remain vague. This study attempts to profile the regulatory networks of circRNA and RBP using a multi‐omics approach. Has_circ_0006646 (circ0006646) is an unreported circRNA in HCC and is associated with a poor prognosis. Silencing of circ0006646 significantly hinders metastasis in vivo. Mechanistically, circ0006646 prevents the interaction between nucleolin (NCL) and the E3 ligase tripartite motif‐containing 21 to reduce the proteasome‐mediated degradation of NCL via K48‐linked polyubiquitylation. Furthermore, the change of NCL expression is proven to affect the phosphorylation levels of multiple proteins and inhibit p53 translation. Moreover, patient‐derived tumor xenograft and lentivirus injection, which is conducted to simulate clinical treatment confirmed the potential therapeutic value. Overall, this study describes the integrated multi‐omics landscape of circRNA‐mediated NCL ubiquitination degradation in HCC metastasis and provides a novel therapeutic target.
- 15 February 2024
- Published by Wiley in Advanced Science
- Vol. 11 (16) , e2306915
Open AccessIntegrated Multiomics Reveals Silencing of has_circ_0006646 Promotes TRIM21‐Mediated NCL Ubiquitination to Inhibit Hepatocellular Carcinoma Metastasis
Recent studies suggest that circular RNA (circRNA)‐mediated post‐translational modification of RNA‐binding proteins (RBP) plays a pivotal role in metastasis of hepatocellular carcinoma (HCC). However, the specific mechanism and potential clinical therapeutic significance remain vague. This study attempts to profile the regulatory networks of circRNA and RBP using a multi‐omics approach. Has_circ_0006646 (circ0006646) is an unreported circRNA in HCC and is associated with a poor prognosis. Silencing of circ0006646 significantly hinders metastasis in vivo. Mechanistically, circ0006646 prevents the interaction between nucleolin (NCL) and the E3 ligase tripartite motif‐containing 21 to reduce the proteasome‐mediated degradation of NCL via K48‐linked polyubiquitylation. Furthermore, the change of NCL expression is proven to affect the phosphorylation levels of multiple proteins and inhibit p53 translation. Moreover, patient‐derived tumor xenograft and lentivirus injection, which is conducted to simulate clinical treatment confirmed the potential therapeutic value. Overall, this study describes the integrated multi‐omics landscape of circRNA‐mediated NCL ubiquitination degradation in HCC metastasis and provides a novel therapeutic target.